share_log

Pfizer | SC TO-I/A: Third party tender offer statement (Amendment)

SEC ·  Sep 14 04:52

Summary by Moomoo AI

Pfizer Inc. has successfully completed its tender offer to modify eligible Performance Share Awards (PSAs) and Total Shareholder Return Units (TSRUs) as detailed in Amendment No. 2 to the Tender Offer Statement on Schedule TO. The offer, which was filed with the Securities and Exchange Commission (SEC), expired on September 12, 2024, at 11:59 p.m. Eastern Time. Following the expiration, Pfizer accepted for modification a total of 1,359,772 Eligible PSAs and 30,360,402 Eligible TSRUs. The modified awards are now subject to the terms and conditions of the 2019 Plan and the applicable award agreements. The vesting and other terms of the Modified PSAs and Modified TSRUs are described in the Schedule TO and the Modification Offer. This final amendment was filed to report the results of the tender offer and to satisfy the disclosure requirements of Rule 13e-4(c)(4) under the Securities Exchange Act of 1934.
Pfizer Inc. has successfully completed its tender offer to modify eligible Performance Share Awards (PSAs) and Total Shareholder Return Units (TSRUs) as detailed in Amendment No. 2 to the Tender Offer Statement on Schedule TO. The offer, which was filed with the Securities and Exchange Commission (SEC), expired on September 12, 2024, at 11:59 p.m. Eastern Time. Following the expiration, Pfizer accepted for modification a total of 1,359,772 Eligible PSAs and 30,360,402 Eligible TSRUs. The modified awards are now subject to the terms and conditions of the 2019 Plan and the applicable award agreements. The vesting and other terms of the Modified PSAs and Modified TSRUs are described in the Schedule TO and the Modification Offer. This final amendment was filed to report the results of the tender offer and to satisfy the disclosure requirements of Rule 13e-4(c)(4) under the Securities Exchange Act of 1934.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more